Opinion|Videos|October 7, 2024
Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors
Key Takeaways
- Combining BCG and PD-1/PD-L1 inhibitors may enhance antitumor activity through complementary mechanisms, potentially improving outcomes in NMIBC.
- BCG stimulates immune response, while PD-1/PD-L1 inhibitors prevent immune evasion, providing a rationale for their combined use.
Panelists discuss how combining BCG with PD-1/PD-L1 inhibitors may enhance antitumor activity compared with using each agent alone, emphasizing the rationale for this combination therapy and its potential to evolve treatment strategies for non–muscle-invasive bladder cancer (NMIBC) while also considering the implications for patient flow in urology practice and the necessity of a multidisciplinary approach.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How might the combination of BCG and PD-1/PD-L1 inhibitors affect antitumor activity compared with using each agent alone?
- What is the rationale for using these therapies in combination?
- How do you think the combination therapies will evolve treatment of non–muscle-invasive bladder cancer (NMIBC)?
- How would the use of PD-1/PD-L1 inhibitors plus BCG in high-risk NMIBC impact patient flow in urology practice?
THE SPEAKER WILL HIGHLIGHT THE IMPORTANCE OF A MULTIDISCIPLINARY APPROACH
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants 510(k) clearance to Break Wave lithotripsy device for kidney stones
2
Practical guide to female pelvic organ–sparing radical cystectomy
3
CaverSTIM device shows initial promise for post-prostatectomy erectile dysfunction
4
Lina Posada Calderon, MD, provides insights on germline BAP1–associated renal cell carcinoma
5